US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

671.11

+9.201.39%

Number of Gainers:98

Number of Losers:48

Number of Flat:7

PE:- -

High:672.66

Open:662.15

Low:661.43

Close:662.00

Volume:116.08M

Turnover:3.16B

Market Cap:464.22B

Float Cap:356.87B

Loading ...

H.C. Wainwright Remains a Buy on Vera Therapeutics (VERA)

EpicQuest Education Group Internatnl Ltd trading resumes

NASDAQ Trade Halt Volatility Trading Pause at 09:41 Am

Press Release: Dingdong (Cayman) Limited Announces the Change of Director

Bowman Consulting Designs, Oversees Providence One-Mile Woonasquatucket River Greenway Extension

Xometry 2027 Outlook Says Manufacturers See Biggest AI Gains in Upstream Design, Costing and Quality Control

Access is Becoming Manufacturing’s Competitive Advantage, According to Xometry's 2027 U.S. Manufacturing Outlook

THOMSON REUTERS

Access Is the New Manufacturing Advantage: Xometry Releases 2027 EMEA Manufacturing Outlook

Summit Therapeutics is Maintained at Equal-Weight by Barclays

dLocal Partners with LinkedIn to Enable Local-Currency Card Payments in Brazil, Mexico, Colombia and Chile

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

RenovoRx announces publication on TAMP platform’s potential

Akari Therapeutics expands IP portfolio with PCT filing for ADC payload

RenovoRx Cites Peer-Reviewed Case Series on TAMP Gemcitabine Delivery in Locally Advanced Pancreatic Cancer

UiPath to Attend NCQA Health Innovation Summit as NCQA Prior-Authorization AI Collaborative Participant

Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment

Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer

Candel Therapeutics Phase 2a NSCLC Study Shows 24.5-Month Median Overall Survival for Aglatimagene Plus Valacyclovir After ICI Failure

Candel Therapeutics - 69% of Patients with Multiple Lesions Show Systemic Clinical Response

THOMSON REUTERS

Candel Therapeutics - Aglatimagene Plus Valacyclovir Well Tolerated; Grade 3 Adverse Events in 13.7% of Patients

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BK4539/news?page=22"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":671.1924,"timestamp":1791562159214,"preClose":661.99634,"halted":0,"volume":116051041,"delay":0,"changeRate":0.013891,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":9.196045,"latestTime":"10-09 12:09:19 EDT","open":662.1523,"high":672.66296,"low":661.43115,"amount":3159678770.932198,"amplitude":0.016967,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.138586,"peRate":113.608055,"turnoverRate":0.009094,"increases":98,"decrements":48,"flats":4,"marketCap":464216287527.0625,"floatMarketCap":356866721861.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":672.66296,"amplitude":0.016967,"preClose":661.99634,"low":661.43115,"pbRate":"5.138586","latestPrice":671.1054,"volume":116075193,"delay":0,"open":662.1523,"prevYearClose":881.5255,"prevWeekClose":665.7447,"prevMonthClose":677.2829,"prevQuarterClose":677.2829,"fiveDayClose":665.7447,"twentyDayClose":693.0266,"sixtyDayClose":732.057,"secType":"PLATE","market":"US","turnoverRate":0.009096,"peRate":113.608055,"marketCap":464171965943.0625,"floatMarketCap":356826911461.5,"timestamp":1791562165222,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":98,"down":48,"flat":7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:22,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672687267","title":"H.C. Wainwright Remains a Buy on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672687267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672687267?lang=en_us&edition=fundamental","pubTime":"2026-10-01 22:36","pubTimestamp":1790865362,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Arthur He CFA reiterated a Buy rating on Vera Therapeutics today and set a price target of $90.00. According to TipRanks, H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LU2324357040.USD","BK4139","BK4585","BK4588","VERA","CFA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672768839","title":"EpicQuest Education Group Internatnl Ltd trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2672768839","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672768839?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:50","pubTimestamp":1790862628,"startTime":"0","endTime":"0","summary":"09:46 EDT EpicQuest Education (EEIQ)Group Internatnl Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-movi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/epicquest-education-group-internatnl-ltd-trading-resumes-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/epicquest-education-group-internatnl-ltd-trading-resumes-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4204","EEIQ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672750432","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:41 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2672750432","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672750432?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:41","pubTimestamp":1790862115,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:41 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nAQN2MLSMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4204","BK4539","EEIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672750552","title":"Press Release: Dingdong (Cayman) Limited Announces the Change of Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2672750552","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672750552?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:25","pubTimestamp":1790861100,"startTime":"0","endTime":"0","summary":"SHANGHAI, Oct. 1, 2026 /PRNewswire/ -- Dingdong (Cayman) Limited (\"Dingdong\" or the \"Company\") (NYSE: DDL), a leading fresh grocery e-commerce company in China, with advanced supply chain capabilities","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DDL","BK4539","BK4551","BK4113"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672757477","title":"Bowman Consulting Designs, Oversees Providence One-Mile Woonasquatucket River Greenway Extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757477","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757477?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:07","pubTimestamp":1790860022,"startTime":"0","endTime":"0","summary":"Bowman Consulting designs, oversees Providence one-mile Woonasquatucket River Greenway extensionBowman Consulting led final design, contract documents, and construction oversight for a one-mile Woonas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL9ShfJY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","BWMN","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672574657","title":"Xometry 2027 Outlook Says Manufacturers See Biggest AI Gains in Upstream Design, Costing and Quality Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2672574657","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672574657?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:05","pubTimestamp":1790859947,"startTime":"0","endTime":"0","summary":"Xometry 2027 outlook says manufacturers see biggest AI gains in upstream design, costing and quality controlXometry published its 2027 U.S. Manufacturing Outlook, arguing competitive advantage is shif","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLcg0CTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","XMTR","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4539","IE00BQXX3F31.USD","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD","BK4104","LU2210149790.SGD","NDAQ","BK4112","LU0314104364.USD","BK4122","IE00BKPKM429.USD","PRNT","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","LU1878469433.USD","BK4561","SG9999014021.USD","BCDF","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672757453","title":"Access is Becoming Manufacturing’s Competitive Advantage, According to Xometry's 2027 U.S. Manufacturing Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757453?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:05","pubTimestamp":1790859900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA2LSLMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4104","BK4122","BK4539","XMTR","LU1878469433.USD","PRNT","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672750338","title":"Access Is the New Manufacturing Advantage: Xometry Releases 2027 EMEA Manufacturing Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2672750338","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672750338?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:05","pubTimestamp":1790859900,"startTime":"0","endTime":"0","summary":"Industrial firms across Europe are turning to AI-powered networks for manufacturing capacity, quality proof, and specialised engineering skillsMUNICH, Oct.  01, 2026 (GLOBE NEWSWIRE) -- Xometry, Inc. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372994/0/en/access-is-the-new-manufacturing-advantage-xometry-releases-2027-emea-manufacturing-outlook.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4122","AGIX","BK4104","EES","ARTY","AIPO","EPV","LU1878469433.USD","QTOC","BK4539","CHAT","XMTR","PRNT","VTHR","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672757170","title":"Summit Therapeutics is Maintained at Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757170","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757170?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:03","pubTimestamp":1790859780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SMMT/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","LENZ","LU2488822045.USD","SMMT","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672571957","title":"dLocal Partners with LinkedIn to Enable Local-Currency Card Payments in Brazil, Mexico, Colombia and Chile","url":"https://stock-news.laohu8.com/highlight/detail?id=2672571957","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672571957?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:02","pubTimestamp":1790859760,"startTime":"0","endTime":"0","summary":"dLocal partners with LinkedIn to enable local-currency card payments in Brazil, Mexico, Colombia and ChiledLocal entered a collaboration with LinkedIn to enable local-currency card payments for member","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6rKnZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","DLO","BK4563","BK4106","BK4227","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672750333","title":"Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672750333","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672750333?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:00","pubTimestamp":1790859600,"startTime":"0","endTime":"0","summary":"Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372931/0/en/lexeo-therapeutics-announces-oral-presentation-of-lx2006-at-the-international-congress-of-parkinson-s-disease-and-movement-disorders-2026-mds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4130","BK4139","FXN","BK4535","FA","LXEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672757619","title":"RenovoRx announces publication on TAMP platform’s potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757619","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757619?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:55","pubTimestamp":1790859337,"startTime":"0","endTime":"0","summary":"RenovoRx (RNXT) announced the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at Hackensack Meridian Health...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-announces-publication-on-tamp-platforms-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-announces-publication-on-tamp-platforms-potential-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672752032","title":"Akari Therapeutics expands IP portfolio with PCT filing for ADC payload","url":"https://stock-news.laohu8.com/highlight/detail?id=2672752032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672752032?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:36","pubTimestamp":1790858214,"startTime":"0","endTime":"0","summary":"Akari Therapeutics (AKTX) announced the filing of PCT/US2026/45955, expanding the Company’s intellectual property portfolio around its novel splici...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/akari-therapeutics-expands-ip-portfolio-with-pct-filing-for-adc-payload-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/akari-therapeutics-expands-ip-portfolio-with-pct-filing-for-adc-payload-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NXTI","LENZ","BK4539","BK4139","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672875225","title":"RenovoRx Cites Peer-Reviewed Case Series on TAMP Gemcitabine Delivery in Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672875225","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672875225?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:32","pubTimestamp":1790857968,"startTime":"0","endTime":"0","summary":"RenovoRx cites peer-reviewed case series on TAMP gemcitabine delivery in locally advanced pancreatic cancerRenovoRx announced a peer-reviewed case series publication on its TAMP platform using the Ren","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL4F8XxD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014039.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","SG9999014021.USD","NDAQ","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014005.SGD","BK4539","BK4588","LU2095319765.USD","IE00BQXX3F31.USD","BCDF","BK4585","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","RNXT","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672752405","title":"UiPath to Attend NCQA Health Innovation Summit as NCQA Prior-Authorization AI Collaborative Participant","url":"https://stock-news.laohu8.com/highlight/detail?id=2672752405","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672752405?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:31","pubTimestamp":1790857876,"startTime":"0","endTime":"0","summary":"UiPath to attend NCQA Health Innovation Summit as NCQA prior-authorization AI collaborative participantUiPath will attend the NCQA Health Innovation Summit in booth #253 on Oct. 4-7, 2026.The company ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL8ldpxY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4551","PATX","PATH","BK4505","BK4588","LU1861558580.USD","BK4547","BK4097","BK4585","LU1861559042.SGD","BK4543","BK4539","BK4561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672521387","title":"Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2672521387","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672521387?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:25","pubTimestamp":1790857500,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics said it saw positive data from a phase 1 study evaluating MRT-8102, which is being developed to treat inflammatory conditions in patients with elevated risk of cardiovascular disease.The company said Thursday the drug, a molecular glue degrader, successfully targeted and degraded NEK7, a type of protein that drives inflammatory conditions, with a median reduction of about 80% to 90% observed across all three dose levels in the study.Both drivers of plaque growth and progression and systemic inflammatory biomarkers were substantially reduced following MRT-8102 administration at all three dose levels to levels comparable with baseline values from healthy volunteers, the company said.The company said the results are encouraging and support the continued development of MRT-8102 in cardiovascular disease and other indications. The company said it expects to initiate multiple Phase 2 studies of MRT-8102 in indications with high unmet need, including stable coronary ar","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CSII","GLUE","BK4139","BK4539","BK4082","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672975265","title":"Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672975265","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672975265?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:15","pubTimestamp":1790856950,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics (WHWK) announced the presentation of two real-world analyses supporting mucin 16 as a durable therapeutic target and potenti...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/whitehawk-therapeutics-presents-real-world-analyses-of-muc16-in-ovarian-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/whitehawk-therapeutics-presents-real-world-analyses-of-muc16-in-ovarian-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","WHWK","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754023","title":"Candel Therapeutics Phase 2a NSCLC Study Shows 24.5-Month Median Overall Survival for Aglatimagene Plus Valacyclovir After ICI Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754023","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754023?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856377,"startTime":"0","endTime":"0","summary":"Candel Therapeutics phase 2a NSCLC study shows 24.5-month median overall survival for aglatimagene plus valacyclovir after ICI failureCandel Therapeutics reported final Phase 2a results in advanced NS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6Rphwx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014039.USD","IE00BQXX3F31.USD","BK4112","IE00BN0W2T93.GBP","BK4139","BK4588","IE00B3QW5Z07.USD","NDAQ","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BCDF","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014013.SGD","SG9999014021.USD","LU2095319765.USD","CADL","BK4539","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672754046","title":"Candel Therapeutics - 69% of Patients with Multiple Lesions Show Systemic Clinical Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2672754046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672754046?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856373,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0OU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","CADL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672275404","title":"Candel Therapeutics - Aglatimagene Plus Valacyclovir Well Tolerated; Grade 3 Adverse Events in 13.7% of Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2672275404","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672275404?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:06","pubTimestamp":1790856373,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0OU:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CADL","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":40,"pageCount":22,"totalSize":782,"code":"91000000","status":"200"}]}}